MUMBAI, India, Aug. 24 -- Intellectual Property India has published a patent application (202641093690 A) filed by Saveetha Institute Of Medical And Technical Sciences on August 03, 2026, for Db-Scut-Same-Synbiotic Nanocapsules For Oral And Gut Dysbiosis Modulation.
Inventors include Dr. Nitya Krishnasamy; Dr. Rajesh Kumar S; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on August 21, 2026, under issue no. 34/2026.
Abstract: Db-Scut-SAME Synbiotic Nanocapsules for oral and gut dysbiosis modulation are disclosed, comprising Desmostachya bipinnata extracts, Scutellarin, and S- adenosylmethionine (SAMe) co-encapsulated within biodegradable nanocapsules to enhance stability, solubility, and targeted delivery. The formulation ensures sustained release of bioactive compounds, providing synergistic anti-inflammatory, antioxidant, antimicrobial, and epigenetic regulatory effects. Designed for oral administration in the form of suspensions, lozenges, gels, mucoadhesive patches, or capsules, the invention offers a natural, safe, and patient-friendly therapeutic strategy for restoring microbial balance, promoting epithelial regeneration, and preventing progression of dysbiosis-associated conditions such as oral potentially malignant disorders, periodontitis, and gastrointestinal inflammation.
Disclaimer: Curated by HT Syndication.
